Our Vision

Harnessing Biomedical Signal Processing to Advance Medicine

At BioSig Technologies, we are dedicated to developing new ways to help patients and physicians. Our first product is the PURE EP™ System, a system designed for use in the large and growing electrophysiology market.

Learn More About BioSig

PURE EP(tm): Our Novel Real-Time Signal Processing Platform

Our first product elevates the standard of care in electrophysiology through enhanced signal acquisition, digital signal processing, and analysis.

Learn more about PURE EP(tm)

BioSig Releases PURE EP Study Abstract with Data Presented at ESC Congress 2020

Positive responses confirm that the PURE EP signals are preferred to conventional sources of intracardiac signals in a blinded, independent analysis. The abstract concludes that the PURE EP System can produce reliable and high-quality signals when compared to the available standard of care systems.

Press ReleaseSeptember 15, 2020

ViralClear to Host Conference Call on September 22 to Discuss Phase 2 Human Trial

ViralClear Pharmaceuticals, Inc. will host a conference call to discuss its randomized, double-blind, placebo-controlled, clinical trial of merimepodib in combination with remdesivir in hospitalized adults with COVID-19 who require non-invasive ventilation/high flow oxygen devices or supplemental oxygen.

Press ReleaseSeptember 9, 2020

BioSig Announces Abstract Acceptance to Computing in Cardiology 2020

BioSig Technologies, Inc.’s abstract for ‘Computational Reconstruction of Electrocardiogram Lead Placement’ was accepted for presentation at the 2020 Computing in Cardiology Conference. The manuscript presents a method for computationally reconstructing the spatial placement of ECG leads.

Press ReleaseJune 29, 2020

BioSig Installs PURE EP System at Massachusetts General Hospital

BioSig Technologies, Inc. has installed its PURE EP System at Massachusetts General Hospital (MGH) as part of an expanding clinical study. BioSig is currently conducting patient cases at Texas Cardiac Arrhythmia Research Foundation (TCARF) in Austin, Texas, and Mayo Clinic in Jacksonville, Florida.

Press ReleaseJuly 4, 2020

Bioelectronic Medicine:
The Leading Edge of Healthcare

Bioelectronic medicine is a new, rapidly growing field of healthcare that explores how targeted electrical signals in the body can help to diagnose and treat a wide range of diseases, from diabetes to depression.
BioSig aims to play a vital role in the field of bioelectronic medicine, based on our unique enabling technology and core competency in signal processing. Our initial focus is on heart disease and the fast-growing electrophysiology device market.

What Is Bioelectronic Medicine?

The Need to Improve Arrhythmia Treatment

Heart Disease Is the
#1 Cause of Death

Arrhythmia, a common cardiac condition, causes the heart to beat too quickly, too slowly, or erratically. New signal processing technologies could play a key role in enhancing outcomes from one of the most important treatments for arrhythmia: catheter ablation.

Challenging, Costly Conditions

The health and economic impacts of arrythmia are immense. The most common arrhythmia, atrial fibrillation (AFib), affects 33 million people worldwide* – generating annual healthcare costs of $15,000 to $25,000 per patient*.

*Worldwide Epidemiology of Atrial Fibrillation in the journal Circulation, 2013; “Healthcare Costs Drop Sharply after Successful Ablation,” Marlene Busko, Medscape, May 4, 2016

Barriers to Treatment Efficacy

Treatment of AFib and ventricular tachycardia typically starts with drug therapy, which is often ineffective, particularly in the later stages of heart disease. Catheter ablation often fails, leading to costly repeat procedures.

The Importance of Signal Clarity

Clearer signal information may help physicians work faster and more accurately during catheter ablation. One of the main reasons for low ablation success rates is unreliable information – specifically, the inability to differentiate between the clean signal and lab noise.

PURE EP™: A Signal Processing Solution

By improving signal clarity, BioSig’s PURE EP™ System has the potential to deliver valuable advances in electrophysiology procedures. We recently conducted first clinical cases at the Texas Cardiac Arrhythmia Institute under the leadership of Andrea Natale, M.D., F.A.C.C., F.H.R.S., F.E.S.C., Executive Medical Director, Texas Cardiac Arrhythmia Institute at St. David’s Medical Center. According to Dr. Natale, early results suggested improved cardiac signal detection and fidelity - click here to read the announcement.

How Does Pure EP™ Work?

Key Scientific Publications

We’re proud of our high success rate for peer-reviewed publications: 9 of the 10 publications we’ve submitted to date have been accepted. These publications provide early evidence that PURE EP™ could offer valuable improvements in signal clarity during electrophysiology procedures.

Browse Our Publications

Looking Beyond Arrhythmia

In 2017, BioSig signed a 10-year strategic collaboration with experts at Mayo Clinic to jointly develop our signal processing technology. These experts see the potential for our technology to help them electrically map the entire body, possibly leading to diagnosis and development of new therapies in other disease areas – for example, neurology and ophthalmology.

Learn About Our Partnerships

Creating Value for Investors

BioSig is a NASDAQ-traded company with a clear path to commercialization and growth, proven credentials for success, and a world-class leadership team. Check out our Investor Resources for financial and governance information, stock performance, SEC filings, and other materials.

See Investor Resources